MedTrace Logo

Phase II Study of Oxaliplatin and Taxotere in Metastatic Bladder Cancer

NCT00186277 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2011-03-30

No results posted yet for this study

Summary

To combine oxaliplatin and taxotere in patients who have had prior cisplatin therapy in bladder cancer.

Conditions

Interventions

DRUG

Oxaliplatin

Calculated per patient

DRUG

Taxotere

Calculated per patient

Sponsors & Collaborators

Principal Investigators

  • Dr. Sandy Srinivas · Stanford University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-12-31
Primary Completion
2006-12-31
Completion
2006-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00186277 on ClinicalTrials.gov